Why the study?
Does ticlopidine, Alka-Seltzer, or aspirin + citric acid improve platelet aggregation inhibition in healthy subjects resistant to aspirin alone?
Does ticlopidine, Alka-Seltzer, or aspirin + citric acid improve platelet aggregation inhibition in healthy subjects resistant to aspirin alone?
In individuals resistant to aspirin alone, ticlopidine and aspirin combined with citric acid provide stronger platelet aggregation inhibition than Alka-Seltzer.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for ticlopidine or aspirin-citric acid in aspirin-resistant subjects; prospective trials needed before any practice change.
Aspirin (ASA) does not effectively lower platelet aggregation in all people. The platelet aggregation (PA) score is an easily used clinical method for measuring the effect in individuals of antiplatelet medications. Fifteen apparently healthy subjects (2 men and 13 women), selected for their resistance to ASA's antiaggregation effect, completed a sequential trial of ticlopidine, Alka-Seltzer, and ASA + citric acid (CTA). Ticlopidine was the strongest aggregation inhibitor and the ASA + CTA combination was more inhibitory than Alka-Seltzer. It was determined that measuring antiaggregation effects of a particular agent in an individual prior to usage would optimize treatment. The PA score methodology provides a means for testing patients prior to antiplatelet therapy for prevention and treatment of the thrombotic complications of vascular disease.
No takes yet. Share an insight, caveat, or question.
Kaplan et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: